TEPEZZA

TEPEZZA (teprotumumab) is a monoclonal antibody insulin-like growth factor-1 receptor inhibitor developed by Amgen and approved by the FDA on January 21, 2020. It is indicated for thyroid eye disease (TED), an inflammatory condition affecting the eye muscles and tissues in patients with Graves' disease. The drug works by blocking IGF-1R signaling, which plays a key role in the pathogenesis of TED, thereby reducing inflammation and preventing disease progression. As the first and only FDA-approved treatment for moderate-to-severe TED, TEPEZZA represents a significant advancement in an area previously lacking targeted therapeutic options.